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Background: Dendritic cells (DC) are professional antigen-presenting cells in the immune system. They patrol the
blood as circulating dendritic cell precursors (DCP). Decreased blood DCP count has been shown to be related to
atherosclerotic plaque burden. Since chronic kidney disease (CKD) is associated with chronic inflammation and
increased cardiovascular risk, the aim of our study was to investigate a potential effect of CKD on circulating DCP
numbers especially in patients with a history of cardiovascular disease.
Methods: The number of circulating myeloid (mDCP), plasmacytoid (pDCP), and total DCP (tDCP) was analysed by
flow cytometry in 245 patients with CKD stage 3 (with and without known cardiovascular events) and 85 coronary
healthy controls. In addition, data were compared with a historical group of 130 patients with known coronary
artery disease (CAD).
Results: Compared to controls, patients with CKD 3 revealed a significant decrease in circulating mDCP (-29%),
pDCP (-43%), and tDCP (-38%) (P < 0.001, respectively). Compared with CAD-patients, the decrease in circulating
DCP in CKD was comparable or even more pronounced indicating a potential role for DCP in cardiovascular risk
potentiation due to CKD.
Conclusions: Based on previous findings in CAD, the marked decrease of DCP in CKD implicates a potential role for
DCP as a mediator of cardiovascular disease. Whether DCP in CKD may act as new cardiovascular biomarkers needs
to be established in future prospective trials.Background
Dendritic cells (DC) which are derived from bone marrow
progenitor cells, are potent antigen-presenting cells. They
play a major role in the initiation and maintenance of
innate and adaptive immunity and are present in nearly
all body tissues forming a dense network [1-3]. These
cells can be found in an immature state in the blood as
DC precursors (DCP). Their main function is to observe
the internal environment to detect foreign potential
harmful antigens [4]. In consequence of antigen uptake
and by presence of inflammatory stimuli, immature DC
undergo terminal differentiation. By this, DC express
different costimulatory molecules and thus stimulate the
immunogenic system [2,5,6].* Correspondence: katharina.paul@med.uni-jena.de
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reproduction in any medium, provided the orIn humans, there are at least two different DC-subpopu-
lations: myeloid DC (mDC) and plasmacytoid DC (pDC).
The mDC are most similar to monocytes. They consist of
two subsets: the more common mDC-1, which is a major
stimulator of T-cells and the extremely rare mDC-2, which
may have a function in fighting wound infection. The
pDC look like plasma cells and are often referred to as
interferon-producing cells, but have certain characteristics
similar to mDC [7].
The amount of circulating DCP is related to immune
status as significant alterations in blood DCP subsets have
been demonstrated in a variety of clinical conditions. Due
to inflammatory and immunological processes in athero-
sclerotic plaques, there are close relationships between
atherosclerosis, inflammation, and the (auto) immune
reactions [3,8].
Previous studies have shown significant changes of the
frequency of circulating DCP in peripheral blood during
inflammation or myocardial infarction [7,9]. Yilmaz et al.. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(mDCP) in patients with different manifestations of cor-
onary artery disease (CAD) such as stable and unstable
angina pectoris as well as acute myocardial infarction.
Based on this observation, recruitment and consumption
of DC in atherosclerotic plaques was discussed as a reason
for their decrease in the circulation. According to this
finding, a significant decrease in circulating levels of
mDCP, pDC precursors (pDCP) and total DC precursors
(tDCP) was described in a large cohort of patients having
stable CAD [11].
Chronic Kidney Disease (CKD) is associated with a high
prevalence of distinct cardiovascular (CV) risk factors
[12,13]. Moreover, CKD itself is an important CV risk
factor. An estimated glomerular filtration rate (eGFR) less
than 60 mL/min/1.73 m2 is an independent predictor
of all-cause and CV mortality [14]. Uremic toxins have
proinflammatory effects and their accumulation represents
a chronic stimulus to inflammatory response. Thus, ele-
vated levels of inflammatory mediators and an increase
in oxidative stress can be observed in CKD [14]. Vascular
changes are initiated and perpetuated by the interaction
of immune cells with cells of the vessel wall [12,13,15].
Atherosclerosis, vascular calcification, or development of
left ventricular hypertrophy and congestive heart failure
are the main causes of CV mortality in CKD [16]. Most of
the patients with CKD die from CV events (CVE), often
before reaching end-stage renal disease (ESRD) [13,16,17].
Patients with CKD stage 3 have a 2 to 4 times higher risk
of CV mortality as compared to patients without CKD
depending on the stage of CKD, the underlying kidney
disease and the extent of albuminuria [18]. In patients
with ESRD, cardiovascular mortality is responsible for
up to 45% of total mortality [14,19]. On that account, the
CV health status of patients with earlier stages of CKD is
of particular importance for the prevention of CVE [13].
Disturbed immunological status may contribute to
proatherosclerotic mechanisms (i.e. by a decrease of
specialized antibodies against plaque antigens or during
elimination of oxidized LDL) [19]. Furthermore in CKD,
the chronic inflammatory state may lead to a reduction of
circulating DCP by consumption in the atherosclerotic
vessel wall. Thus, circulating DCP may act as a new
biomarker for latent inflammatory processes, probably
due to vascular disease and may furthermore reflect
plaque burden.
There are less profound data regarding the number of
circulating DCP in patients with CKD stage 3. Hesselink
et al. [5] detected a decrease in circulating DCP in patients
with CKD stage 5 compared to healthy volunteers.
The aim of this investigation was to analyse the level of
circulating DCP in patients with CKD stage 3 with and
without a history of CVE. Findings were compared with
DCP counts of coronary healthy controls and patientswith known CAD in order to determine coherencies of
CV status, DCP count and kidney function.
Methods
Participants
Patients with CKD stage 3 with and without a history of
CVE were enrolled within the German Chronic Kidney
Disease Study (GCKD), which is a German national cohort
study [20]. Based on the GCKD protocol [20], 245 patients
with CKD stage 3 were included in our cross-sectional
study. All patients were recruited in the GCKD regional
center of Jena between January and August 2011. In brief,
for GCKD, patients are screened to fulfill the criteria of an
eGFR between 30-60 mL/min calculated by the 4-variable
MDRD formula. Main criteria for exclusion from the
GCKD study are described elsewhere [20]. The underlying
kidney diseases of this substudy cohort were as follows:
33% hypertensive nephropathy, 17% diabetic nephropathy,
11% glomerulonephritis, 10% interstitial nephritis, 4% poly-
cystic kidney disease and 1% vascular nephropathy, 24%
miscellaneaous.
CKD 3 patients who already had myocardial infarction,
stroke, peripheral artery disease, or patients who underwent
coronary revascularization by intracoronary stenting/
balloon dilatation or coronary artery bypass grafting were
defined as patients with a history of CVE. The remaining
CKD 3 patients were defined as CKD 3 patients without
history of CVE.
Eighty-five otherwise healthy individuals served as
coronary healthy controls. They had angina-like symptoms
and therefore underwent coronary angiography which led
to the exclusion of CAD in all cases. Relevant CKD (by an
eGFR <60 mL/min) was excluded in the coronary healthy
control group as well as in the CAD group.
Furthermore, data were compared with a well-described
cohort of patients having stable CAD, described in 2009
by Yilmaz et al. [11]. In these patients, based on the
results of coronary angiography, a CAD score was calcu-
lated as follows: early CAD (score 1 - 5; n = 43), moderate
CAD (score 6 - 10; n = 42) and advanced CAD (score > 10;
n = 45) [4].
Moreover, for the present investigation, the intake of
any immunosuppressive drugs or suffering from diseases
that could interfere with our analysis e.g. any kind of infec-
tions, malignancies, autoimmune diseases, and hyperthyr-
eoidism were excluded in patients and controls.
Description of procedures or investigations undertaken
Blood samples from controls and patients were collected
in 9 mL EDTA tubes and immediately cooled (4 -10°C).
Samples were analysed by flow cytometry for circulating
DCP within 8 h after the collection. The survival and
stability of DCP was tested before. Samples were analysed
for DCP immediately, after 8 hours and after 24 hours. By
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not shown). For routine blood analyses, especially leukocyte
count, the same blood sample as for DCP analysis
was used. Routine blood analyses were performed by
standardised techniques in the central laboratories of the
university hospitals of Jena and Erlangen and in the
laboratories of Synlab® Labordienstleistungen (core data
set of GCKD). For conventional CRP measurement the
lower detection limit was 2 mg/L.
Using the Blood Dendritic Cell Enumeration kit™ (BDCA
kit; Miltenyi Biotec) circulating mDCP and pDCP were
analysed by four-colour staining and FACS analysis in
fresh blood samples collected in tubes containing EDTA.
Circulating mDCP and pDCP were identified according to
their expression of BDCA-1, BDCA-2 and the absence of
the expression of other peripheral blood mononuclear cell
(PBMC) markers. Thus the cells were classified according
to CD 303, CD1c, CD14, CD19 and CD141. For this
purpose, 300 μL of blood were mixed with 20 μL of the
control cocktail for isotype control and 300 μL of blood
were mixed with 20 μL of the anti-BDCA cocktail for
cell staining. In order to discriminate dead cells, 10 μL
of a fluorescent cell-impermeant dye (which binds to
nucleic acids of dead cells) were added and samples
were incubated for 10 min under 60 W light bulb. After
cell staining, erythrocytes were lysed using the red blood
cell lysis solution from the Blood Dendritic Cell Enumer-
ation kit™ (BDCA kit; Miltenyi Biotec). Cells are then
washed and fixed using fix solution. Another solution was
added to the samples for optimal dead cell discrimination
even after prolonged storage (Miltenyi Biotec).
Finally, cells were analysed using FACSCalibur flow
cytometer with CellQuest software (Becton Dickinson). As
circulating DCP comprise only 0.1-1% of white blood cells
(WBC), a special gating strategy to exactly analyse the
number of mDCP, pDCP, and tDCP was used. In Region
R1 2*105 white blood cells (WBC) were registered defined
by forward scatter (FSC) and side scatter (SSC). In Region
R2, granulocytes were excluded according to their high
SSC and lymphocytes, monocytes, and dead cells were
excluded according to their CD19, CD14, and propidium
iodide staining. Circulating mDCP and pDCP were de-
tected due to their specific staining for BDCA-1 and
BDCA-2 in regions R3 and R4 and total DCP (tDCP)
were the sum of cells in region R3 and R4 (Figure 1).
Thus, the relative cell numbers of circulating DCP were
determined as percentage of WBC. Subsequently, the
absolute cell numbers (cells/μL) were assessed by multi-
plying the relative cell numbers with the individual
WBC count, which was measured in routine laboratory
in the same blood sample. The current investigations as
well as the historical CAD cohort were measured by the
use of the same laboratory methods including the same
type of flow cytometer (FACSCalibur).For measurement standardisation, a daily and monthly
calibration of the flow cytometer was done. Moreover
for reliable enumeration of DCP, an isotype control
sample was always included for compensation of variations
between the measurements.
Ethics
The study was carried out in accordance with the Declar-
ation of Helsinki (2000) and was approved by the institu-
tional ethics committees from the University of Jena and
Erlangen. Written informed consent was obtained from all
participants.
Statistical methods
All values are expressed as medians (minimum, maximum)
and means (± standard deviation) or percentages, as appro-
priate. A P-value of < 0.05 was considered to state statistical
significance. Student’s t-test (for normal distribution)
and Mann-Whitney Rank Sum test (for not-normally
distributed data) were used for the comparison between
two independent groups. There was no logarithmic (or
other) transformation as the data was tested for normal
distribution. Categorical clinical data (e.g. gender, presence
of hypertension, smoking, diabetic comorbidity) were
compared using chi-square statistics. Kruskal-Wallis Test
or chi-square statistics were performed for comparison of
all 3 groups. Correlation analyses were performed using
Pearson Product Moment Correlation for normally distrib-
uted data or Spearman Rank Order Test for not-normally
distributed data. Controls, CKD 3 and CAD patients differ
in several factors (e.g. age, gender), which may influence
DCP counts. Therefore a linear regression was performed
using DCP count as dependent variable (Additional file 1).
Age, male gender, diabetes mellitus, hypertension, smoking,
CRP, leukocyte count, GFR, creatinine, cholesterol, HDL,
LDL and TG and group dependence were analysed as
independent variables. For group dependency, CKD 3 pa-
tients were used as the reference group. Data analysis was
performed using SigmaStat 3.0® software, SPSS (SPSS Inc.,
USA), version 19 and Prism 4.0 (GraphPad Software, Inc.).
Results
Study population
Clinical data of 245 patients with CKD stage 3 out of the
GCKD study cohort [20], 130 patients with stable CAD
and 85 coronary healthy controls are shown in Table 1.
There was no significant correlation between gender and
circulating DCP in the control group (data not shown),
whereas a weak correlation of mDCP (r = -0.21, P = 0.05)
but not pDCP with age was found.
No significant differences between controls and CKD 3
patients were observed concerning smoking status and C-
reactive protein (CRP). Compared to coronary healthy con-
trols, patients with CKD stage 3 were different concerning
Figure 1 Gating strategy used for the identification of circulating mDCP, pDCP, and tDCP by flow cytometry. Region R1 white blood
cells (WBC) were separated from debris and platelets using their forward and side scatter (FSC and SSC). Region R2 was used to exclude
granulocytes by SSC, B lymphocytes by CD19 staining, monocytes by CD14 staining, and dead cells by propidium iodide-staining. In regions R3
and R4, circulating mDCP and pDCP were detected according to their specific BDCA-1 and BDCA-2 staining, respectively.
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respectively), male gender (P = 0.010), leukocyte count
(P = 0.004), values of total cholesterol (P = 0.010) and HDL
(P = 0.014, Table 1).
Compared to CAD patients, CKD 3 patients were not
different concerning age, male gender, smoking, CRP,
values of total cholesterol and HDL. CKD 3 patients
suffered more often from diabetes mellitus and hyperten-
sion (P < 0.001, respectively), and had higher values of TG
(P = 0.018). Instead of this, CAD patients had higher values
of leukocytes, and LDL cholesterol (P < 0.001, respectively,
Table 1).
In the CAD-subgroups according to their different
CAD scores, there was no significant difference or trend
concerning GFR.Circulating DCP in patients with CKD stage 3 vs. controls
Numbers of circulating mDCP, pDCP, and tDCP of
controls, patients with CKD stage 3 and CAD patients are
given in Table 1.
In patients with CKD stage 3, significant lower absolute
(Figure 2) and relative numbers (P < 0.001, respectively) of
circulating mDCP, pDCP, and tDCP were observed as
compared to the control group. Thus, CKD 3 patients had
29% lower absolute numbers of circulating mDCP than
controls (P < 0.001). Considering pDCP, CKD 3 patients
had also significant lower absolute numbers (43% lower)
than the control group (P < 0.001). Concordantly, absolute
tDCP were significantly lower in patients with CKD stage
3 than in controls (P < 0.001; Figure 2).
Since relative and absolute numbers of circulating
DCP were reduced, the possibility that this decrease was
caused by a dilution phenomenon due to an increase of
another PBMC could be safely excluded.
Circulating DCP in patients with CKD stage 3 vs. CAD
For the evaluation of potential coherencies in cardiovascu-
lar risk due to DCP changes in patients with proven CADof different severity [11] and those with CKD stage 3, their
levels of circulating DCP were compared (Figure 2).
In patients with CAD, a significant severity-dependent
decrease in circulating DCP was observed. Patients with
mild CAD had significant higher numbers of circulating
mDCP, pDCP, and tDCP than patients with advanced
CAD (P < 0.001, Figure 2) [11].
In patients with CKD stage 3, absolute numbers of
circulating mDCP, pDCP, and tDCP were significantly
reduced compared to CAD patients of each score. For
CKD 3 vs. advanced CAD, differences were as follows:
absolute mDCP (23% lower in CKD 3, P = 0.003), pDCP
(19% lower, P = 0.01) and tDCP (28% lower, P < 0.001,
Figure 2).
In linear regression analysis, even after adjustment for
potential confounders (see method section), the absolute
numbers of mDCP, pDCP, and tDCP in the CKD 3 group
remained significantly reduced as compared to controls
and CAD patients (P < 0.001, respectively, see Additional
file 1).Circulating DCP in CKD 3 patients with CVE vs. CKD 3
patients without CVE
In CKD 3 patients having previous CVE compared to
those without CVE, a significant reduction in DCP was
observed for the relative numbers of mDCP (0.15% of
WBC in CKD 3 with CVE vs. 0.18% of WBC in CKD 3
without CVE, P = 0.011) and tDCP (0.23% of WBC in
CKD 3 with CVE vs. 0.27% of WBC in CKD 3 without
CVE, P = 0.003), the absolute numbers of DCP tended
to be reduced (Figure 2, for absolute numbers of DCP).Estimated GFR and DCP
As illustrated in Figure 3, there was a significant posi-
tive correlation between eGFR and circulating DCP in
controls and CKD 3 patients without CVE (P < 0.0001,
respectively).
Table 1 Clinical data of patients with CKD 3, CAD and control group
Control CKD 3 P-Value1 CAD P-Value2 P-Value3
(n = 85) (n = 245) (n = 130)
Age (years) 58 (21, 78) 66 (30, 75) < 0.00 66 (38, 85) n.s. < 0.001
58 ± 11 64 ± 9 64 ± 11
Male gender (%) 43 60 0.010 57 n.s. 0.035
Diabetes mellitus (%) 13 38 < 0.001 15 < 0.001 < 0.001
Hypertension (%) 71 90 < 0.001 72 < 0.001 < 0.001
Smoking (%)
(current and ex-smoking)
38 51 n.s. 43 n.s. n.s.
C-Reactive protein (mg/L) 2.0 (2.0, 9.0) 2.1 (2.0, 9.4) n.s. 2.0 (2.0, 9.0) n.s. n.s.
2.9 ± 1.5 3.3 ± 1.9 3.3 ± 1.9
Leukocytes (Gpt/L) 6.9 (4.2, 12.0) 6.4 (3.6, 12.7) 0.004 7.3 (3.7, 17.1) < 0.001 < 0.001
7.1 ± 1.5 6.5 ± 1.6 7.5 ± 2.3
GFR (mL/min/1.73 m2) 83 (60, 215) 46 (30, 60) < 0.001 72 (60, 119) < 0.001 < 0.001
85 ± 20 45 ± 9 75 ± 11
Creatinine (mg/dL) 0.88 (0.34, 1.26) 1.46 (0.75, 3.35) < 0.001 0.98 (0.69, 1.30) < 0.001 < 0.001
0.87 ± 0.15 1.52 ± 0.46 1.00 ± 0.14
Cholesterol (mg/dL) 217 (121, 328) 203 (91, 411) 0.001 198 (108, 355) n.s. 0.008
222 ± 47 206 ± 49 201 ± 46
HDL (mg/dL) 56 (24, 108) 48 (21, 119) 0.014 47 (31, 82) n.s. 0.012
56 ± 17 51 ± 17 49 ± 11
LDL (mg/dL) 135 (65, 218) 109 (21, 278) < 0.001 131 (64, 226) < 0.001 < 0.001
141 ± 37 113 ± 43 132 ± 35
TG (mg/dL) 127 (48, 514) 184 (37, 806) < 0.001 147 (44, 756) 0.018 < 0.001
148 ± 80 203 ± 117 176 ± 108
DCP count
mDCP rel. 0.22 (0.09, 0.58) 0.17 (0.04, 0.44) < 0.001 0.21 (0.01, 0.47) <0.001 < 0.001
(% of WBC) 0.24 ± 0.10 0.18 ± 0.07 0.22 ± 0.10
pDCP rel. 0.13 (0.04, 0.30) 0.08 (0.02, 0.40) < 0.001 0.11 (0.00, 0.32) < 0.001 < 0.001
(% of WBC) 0.14 ± 0.06 0.09 ± 0.04 0.11 ± 0.06
tDCP rel. 0.38 (0.15, 0.76) 0.26 (0.09, 0.58) < 0.001 0.34 (0.02, 0.72) < 0.001 < 0.001
(% of WBC) 0.39 ± 0.13 0.27 ± 0.10 0.34 ± 0.14
mDCP abs. 15.3 (5.2, 34.4) 10.8 (3.2, 35.6) < 0.001 14.8 (1.5, 35.0) <0.0001 < 0.001
(cells per μL) 16.8 ± 7.2 11.4 ± 4.7 15.8 ± 7.0
pDCP abs. 8.9 (2.5, 16.5) 5.0 (1.1, 16.7) < 0.001 7.4 (0.0, 25.8) < 0.001 < 0.001
(cells per μL) 9.2 ± 3.7 5.5 ± 2.7 8.4 ± 5.2
tDCP abs. 27.3 (9.6, 67.8) 16.8 (4.3, 46.2) < 0.001 24.1 (1.7, 48.8) < 0.001 < 0.001
(cells per μL) 27.2 ± 10.0 17.5 ± 6.1 25.1 ± 10.5
1CKD 3 compared to control.
2CAD compared to CKD 3.
According to Student’s t-test, Mann-Whitney-test or chi-square statistics, as appropriate.
3For differences between any group, according to Kruskal-Wallis-Test or chi-square statistics as appropriate.
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According to linear regression analysis, the CRP level had no
significant influence on the reduction of DCP in CKD 3 pa-
tients as compared to controls and CAD patients (Additionalfile 1). In patients without any known CAD (controls and
CKD 3 patients without CVE), only a weak inverse correl-
ation between CRP and mDCP (r = -0.17, P= 0.007) and
tDCP (r = -0.16, P= 0.009) was found (Figure 4).
Figure 2 Absolute numbers of circulating mDCP, pDCP, and tDCP in controls, CAD and CKD 3 patients. Absolute numbers of circulating
mDCP (A), pDCP (B), and tDCP (C) (cells/μL) in 85 coronary healthy controls, 130 CAD patients, divided into 3 CAD Scores 1-5 (n = 43), 6-10
(n = 42), >10 (n = 45), and CKD 3 patients without (n = 182) and with (n = 63) CVE (Mann-Whitney-test). Box plots indicate the median (line inside
the box), 25th and 75th percentile (lower and upper boundary of the box), and 10th and 90th percentile (whiskers outside the box).
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CV risk is significantly increased in patients with CKD
of any stage. Patients having ESRD are at the highest risk
[21]. However, a large number of patients do not reach
ESRD because of an earlier death due to CVE. Thus, the
CV health status of patients with CKD is of interest for a
successful prevention of CVD. Therefore the search for
new CV biomarkers is important in CKD patients [13].
In the present study, we investigated the number of
circulating DCP in patients with CKD stage 3 compared to
coronary healthy controls and patients with stable CAD. A
significant decrease of circulating mDCP, pDCP, and tDCP
was found in CKD 3 patients compared to controls and
patients with known CAD. Although the groups differed
in several parameters, linear regression confirmed our
findings even if adjusted for possible confounders.
By the current study, a decrease in circulating DCP
could be shown in a substantial number of patients with
a stage of CKD earlier than ESRD. Previous studies in
CKD analysed circulating DCP only in relatively low
numbers of patients, predominantly with ESRD. AgrawalFigure 3 Correlation of absolute numbers of circulating mDCP, pDCP
Absolute numbers of circulating mDCP (A), pDCP (B), and tDCP (C) (cells/μ
without CVE were correlated with the corresponding eGFR (mL/min) (Speaet al. [2] showed that the pDCP and tDCP count of
patients with advanced CKD on dialysis was significantly
lower compared to controls. DCP declined further after
dialysis, which was explained by the migration to tissues
or the accumulation in the dialyzer and tubing system.
Lim et al. [3] already observed decreased relative DCP
numbers in patients with CKD without the need for renal
replacement therapy (n = 10, eGFR >50mL/min) and renal
transplant recipients.
In CAD patients, however, a significant decrease in
circulating DCP compared to controls is well-described
[11,22]. In our study, even if compared with patients
having advanced CAD, CKD 3 patients had signifi-
cantly lower numbers of mDCP, pDCP, and tDCP
probably reflecting a link to CV risk potentiation in this
population. Circulating DCP were significantly reduced
in both, CKD 3 without known CAD and advanced CAD
without CKD.
In previous studies [11,22], a comparable decrease in
circulating DCP was shown for patients with stable and
unstable CAD compared with healthy controls (CAD, tDCP with eGFR in controls and CKD 3 patients without CVE.
L) of 85 coronary healthy controls and 182 patients with CKD stage 3
rman Rank test).
Figure 4 Correlation of absolute numbers of circulating mDCP, pDCP, tDCP with CRP in controls and CKD 3 patients without CVE.
Absolute numbers of circulating mDCP (A), pDCP (B), and tDCP (C) (cells/μL) of 85 coronary healthy controls and 182 patients with CKD stage 3
without CVE were correlated with the corresponding CRP (mg/L) (Spearman Rank test).
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decrease in circulating mDCP observed by Yilmaz et al.
[10] revealed another possibility for CV risk prediction as
mDCP were significantly reduced even at a stable stage
of coronary atherosclerosis. The mDCP are known to be
involved in the inflammatory processes related to athero-
sclerosis. They are present in atherosclerotic plaques [4].
Their number increases in the vascular vessel wall de-
pending on the stage of atherosclerosis, furthermore
they promote plaque destabilization [10,11]. In contrast,
pDCP counts were only slightly reduced in patients with
CAD according to their different migration pattern,
function, turnover, kinetics, migration signals, and the
different role of both subsets in atherogenesis [10].
However, van Vré et al. [22] detected significantly lower
relative and absolute numbers of circulating pDCP in
patients with CAD, whereas for mDCP a reduction was
observed only by trend. The reason for this discrepancy
might be that pDCP are specialized in the modulation
of immune responses concerning strength, duration, and
quality. Depending on the stimulus, pDCP may become
either immunostimulating or tolerogenic. Consequently,
pDCP have been detected in inflamed peripheral tissues
[23]. Van Brussel et al. [24] found a significant reduction
in both mDCP and pDCP in patients with stable angina
pectoris and proven CAD. In contrast to these studies, Shi
et al. [25] observed an increase in relative and absolute
numbers of mDCP in men with proven CAD but pDCP
were similar to healthy controls.
A severity-dependent decrease in circulating mDCP,
pDCP, and tDCP was shown in patients with CAD
underlining the significant association between the decline
of circulating DCP and the extent of CAD [11,22]. In the
present study, a significant reduction of relative mDCP
and tDCP numbers was observed in CKD 3 patients
with CVE compared to those without previous CVE.
The absolute numbers of mDCP, pDCP, and tDCP in CKD
3 patients with CVE tended also to be reduced comparedwith those CKD 3 patients without CVE. Moreover, even
CKD 3 patients without CVE had significantly reduced
absolute numbers of mDCP, pDCP, and tDCP compared
with patients having advanced CAD. If DCP are considered
to serve as possible CV biomarkers, this may be interpreted
as a sign of CV risk equivalency between CKD 3 without
CAD and CAD without CKD, at least with respect to
DCP counts.
There was a significant positive correlation between the
number of DCP and eGFR confirming previous findings
[3]. The reasons for that are unknown so far. A reversible
functional impairment between renal function and DCP
generation is discussed [6]. Moreover, a negative impact of
the uremic milieu on DC function could be demonstrated
[26]. Monocyte-derived DC from patients with advanced
CKD showed depressed endocytosis and impaired matur-
ation but increased cytokine production and T-cell prolifer-
ation when cultured with uremic sera [26]. The influence
of the uremic state on DC generation and function could
also be a reason for the decrease in circulating DCP even
at CKD stage 3. It can be speculated whether vitamin D
deficiency or impaired vitamin D metabolism which both
are present in CKD are of importance for this phenomenon.
Poor vitamin D status indicates an increased CV risk and
could be linked to a compromised innate immune response
[27,28]. Thus, Takeda et al. demonstrated that oral calcitriol
administration led to a marked reduction in atherosclerotic
lesion formation in a mouse model. This reduction was
explained by the suppression of immune reactions, espe-
cially by changing the function or differentiation of DC and
regulatory T-cells [29]. Reduced production of DCP in the
bone marrow is also possible but patients with CKD stage
5 showed no deficiencies in serum levels of granulocyte
macrophage colony-stimulating factor (GM-CSF), a DC
mobilizing cytokine [3]. Levels of leukocyte subpopulations
other than DC were not reduced in the blood of our CKD
cohort (data not shown). Whether increased apoptosis of
circulating DCP due to CKD contributes to reduced DCP
Paul et al. BMC Nephrology 2013, 14:274 Page 8 of 10
http://www.biomedcentral.com/1471-2369/14/274levels needs to be established. Another reason for a de-
crease in DCP could be an increased recruitment and
elevated turnover of circulating DCP in chronically in-
flamed tissues all over the body including the vessel wall.
Several studies about DCP reduction in patients with
atherosclerosis and CVD describe a stage-dependent
accumulation of mDC and pDC in vascular lesions [11,22].
Recruitment of mDC from blood into the intima is induced
by several proatherogenic factors which also suppress the
recirculation of mDC from the vessel wall into the blood
[11,22]. Moreover, recent studies from our group detected
significantly elevated levels of mDC in the infarcted area
of patients with myocardial infarction compared to healthy
myocardium highlighting enhanced recruitment and
consumption of DCP into the target tissue as well as el-
evated recruitment of inflammatory cells like macrophages
and T cells [9].
Furthermore there was a weak but significant inverse
correlation between CRP and mDCP and tDCP. Van Vré
et al. [30] showed that an increased CRP level leads to
the activation of mDC and an increased expression of
DC maturation markers in vitro. Moreover a decreased
migration of mDC was observed in response to increasing
concentrations of CRP [30]. The number of pDC was un-
affected [30,31] as it was the case for pDCP in our study.
Although linear regression did not show a significant
influence of age on our findings, there was a weak influence
of age on DCP in the control group. Concerning this, it
is known that aging is characterized by a decline in
immune functions and by manifold changes in the micro-
environment that could affect activation and/or maturation
of DC [32,33]. Accordingly, Hawiger et al. [34] observed
an increased age-associated circulation of proinflammatory
mediators that can trigger the activation and maturation
of DC.Conclusion
Dendritic cell precursors are significantly decreased in pa-
tients with CKD stage 3 as compared to coronary healthy
subjects and patients with CAD. Circulating DCP might be
of relevance for CV risk potentiation in patients with CKD.
Whether circulating DCP in CKD may act as new CV
biomarkers needs to be established in prospective endpoint
studies. Since DCP correlate positively with eGFR, the
causes for DCP reduction in CKD need to be investigated.Limitations
Whether CKD 3 patients without CVE might have suffered
from clinically silent CAD cannot be excluded since a
coronary angiography was not undertaken in this previously
cardiovascular healthy cohort. Furthermore, CAD-patients
were recruited in the University hospital of Erlangen during
a different period of time than the CKD 3 patients.Additional file
Additional file 1: Linear regression analysis - results. A linear
regression was performed using DCP count as dependent variables. Age,
male gender, diabetes mellitus, hypertension, smoking, CRP, leukocyte
count, GFR, creatinine, cholesterol, HDL, LDL and TG and group
dependence were analysed as independent variables. For group
dependency, CKD patients were used as the reference group. As a result
the absolute mDCP, pDCP, and tDCP numbers in the CKD 3 group
remained significant reduced compared to controls and CAD patients
even if adjusted for the confounders (P < 0.001, respectively).
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